Christopher C Coss

Title: Christopher C Coss: Innovator in Selective Androgen Receptor Degraders

Introduction

Christopher C Coss is a prominent inventor based in Upper Arlington, OH (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective androgen receptor degraders (SARDs). With a total of 12 patents to his name, Coss has been at the forefront of innovative solutions for various medical conditions.

Latest Patents

Coss's latest patents include groundbreaking inventions related to selective androgen receptor degrader (SARD) ligands. One of his notable inventions provides novel compounds such as indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole. These compounds are designed for pharmaceutical compositions aimed at treating hyperproliferations of the prostate, including pre-malignancies, benign prostatic hyperplasia, and prostate cancer. Additionally, his work addresses advanced prostate cancer, castration-resistant prostate cancer, and other androgen receptor-expressing cancers. Another patent focuses on 3-amino propanamide selective androgen receptor degrader compounds, which also target similar medical conditions.

Career Highlights

Throughout his career, Christopher C Coss has worked with esteemed organizations such as the University of Tennessee Research Foundation and Gtx Corporation. His experience in these institutions has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Coss has collaborated with notable professionals in his field, including James T Dalton and Ramesh Narayanan. These partnerships have further enhanced his research and development efforts, leading to significant breakthroughs in the pharmaceutical industry.

Conclusion

Christopher C Coss is a distinguished inventor whose work in selective androgen receptor degraders has the potential to transform the treatment landscape for various medical conditions. His dedication to innovation and collaboration continues to drive advancements in the field of pharmaceuticals.